500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
NCT03695341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130
Last updated 2019-06-18
Summary
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-14
- Primary Completion
- 2019-03-10
- Completion
- 2019-05-15
Countries
- China
Study Locations
More Related Trials
-
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
NCT05000736 ·Status: UNKNOWN
-
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298 ·Status: RECRUITING ·Phase: PHASE3
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT07235618 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
NCT03312738 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
NCT04498481 ·Status: COMPLETED
-
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
NCT05075512 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
NCT05191914 ·Status: UNKNOWN ·Phase: PHASE4
-
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
NCT02025712 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
NCT03939871 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
NCT01633060 ·Status: TERMINATED ·Phase: PHASE3
-
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
NCT05853432 ·Status: COMPLETED
-
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
NCT05054751 ·Status: COMPLETED ·Phase: PHASE3
-
Faslodex Advanced Breast Cancer Local Chinese Study
NCT00327769 ·Status: COMPLETED ·Phase: PHASE3
-
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
NCT05433480 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
NCT01610284 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
NCT01658033 ·Status: COMPLETED ·Phase: PHASE2
-
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
NCT03538171 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
NCT05806047 ·Status: UNKNOWN ·Phase: PHASE2
-
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06635447 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
NCT05054166 ·Status: COMPLETED
-
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
NCT05949541 ·Status: RECRUITING ·Phase: PHASE2